COVID-19 Test Accurately Identifies Specific Variants
Complete the form below to unlock access to ALL audio articles.
University of California, Irvine researchers have developed a COVID-19 test that detects and identifies specific SARS-CoV-2 variants with 100% accuracy. In a study, the RNA-encoded viral nucleic acid analytic reporter correctly determined the alpha, gamma, delta, epsilon and omicron genetic mutations in nasopharyngeal clinical samples. This ability could enable healthcare providers to make personalized treatment decisions for improved patient care.
Recently published online in the Journal of the American Chemical Society, a paper on the research describes the design and validation of the Revealr SARS-CoV-2 genotyping system.
“The COVID-19 pandemic has created an urgent need for individualized diagnostic tools that can recognize the presence of the virus as well as the particular strain. Identifying and triaging patients infected with variants that increase viral transmissibility and reduce vaccine protection is critical to controlling spread of the disease,” said corresponding author John Chaput, UCI professor of pharmaceutical sciences. “Revealr goes beyond simple COVID detection methods, such as the commonly used antigen kit, to identify the precise SARS-CoV-2 strain infecting a patient.”
The team analyzed 34 clinical samples collected in early, mid- and late 2021 at the UCI Medical Center from patients experiencing COVID-19 symptoms. The RNA was isolated from the nasopharyngeal swabs, and the correct SARS-CoV-2 variant was identified in every case.
“Although Revealr was developed as a COVID detection assay, the next step is to expand to other respiratory tract infections that share symptoms with COVID-19, like influenza,” Chaput said. “The ability to distinguish single-point mutation in a DNA or RNA genetic sequence makes it ideally suited for any genotyping, including cancer. Beyond human health, Revealr could find use in forensic or agricultural applications that currently rely on DNA sequencing.”
Reference: Yang K, Schuder DN, Ngor AK, Chaput JC. Revealr-based genotyping of sars-cov-2 variants of concern in clinical samples. J Am Chem Soc. 2022;144(26):11685-11692. doi: 10.1021/jacs.2c03420
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
